Ignite Creation Date:
2024-05-06 @ 5:44 PM
Last Modification Date:
2024-10-26 @ 2:35 PM
Study NCT ID:
NCT05418309
Status:
UNKNOWN
Last Update Posted:
2022-06-14
First Post:
2022-06-09
Brief Title:
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable a Multi-center Study
Sponsor:
Tianjin Medical University Second Hospital
Organization:
Tianjin Medical University Second Hospital
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-12-27
Start Date Type:
ACTUAL
Primary Completion Date:
2024-02
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-07
Completion Date Type:
ESTIMATED
First Submit Date:
2022-06-09
First Submit QC Date:
June 9 2022
Study First Post Date:
2022-06-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-06-09
Last Update Post Date:
2022-06-14
Last Update Post Date Type:
ACTUAL